Clinical Trial: Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07853131) titled 'Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function' on Sept. 23.

Brief Summary: The purpose of this Phase 1, open-label, 2-arm study is to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75 years.

The total duration of the study per participant will be approximately 30 days, including:

* A screening period of up to 27 days.

* A 3-day, open-label treatment period, with a single dose ...